Prognostic factors in chronic lymphocytic leukaemia: tl response to treatment in survival.

British Journal of Haematology 72, 141-149 DOI: 10.1111/j.1365-2141.1989.tb07674.x

Citation Report

#	Article	IF	CITATIONS
1	Prognostic factors in stage AO B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 1990, 76, 348-351.	2.5	16
2	Natural history of stage A chronic lymphocytic leukaemia untreated patients. British Journal of Haematology, 1990, 76, 45-57.	2.5	78
3	Oestrogen receptor (ER) analysis in B-cell chronic lymphocytic leukemia: Correlation of biochemical and immunocytochemical methods. Leukemia Research, 1990, 14, 949-952.	0.8	17
4	Presenting features and prognosis of chronic lymphocytic leukemia in younger adults [see comments]. Blood, 1991, 78, 1545-1551.	1.4	106
5	The Treatment of CLL: Summing up. Leukemia and Lymphoma, 1991, 5, 149-150.	1.3	2
6	The Classification of Lymphoid Leukaemias. Leukemia and Lymphoma, 1991, 5, 153-155.	1.3	8
7	Chronic Lymphocytic Leukemia (B-CLL) and Immunocytoma (LP-IC): Clinical and Prognostic Relevance of this Distinction. Leukemia and Lymphoma, 1991, 5, 161-173.	1.3	8
8	Immunohistochemical detection of the multidrug transport protein P1 70 in human normal tissues and malignant lymphomas. Histopathology, 1991, 19, 131-140.	2.9	94
9	The roles of age and sex in the prognosis of chronic leukaemias. A study of 373 cases. British Journal of Cancer, 1991, 64, 345-348.	6.4	10
10	Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. British Journal of Haematology, 1991, 78, 206-209.	2.5	169
11	New modalities of therapy in chronic lymphocytic leukemia. Critical Reviews in Oncology/Hematology, 1991, 11, 167-177.	4.4	4
12	Expression of myelomonocytic antigens is associated with unfavourable clinicoprognostic factors in B-cell chronic lymphocytic leukaemia. Annals of Oncology, 1991, 2, 107-113.	1.2	75
13	Allogeneic Bone Marrow Transplantation in Chronic Lymphocytic Leukemia: 17 Cases. Report of the EBMT. Leukemia and Lymphoma, 1991, 5, 127-131.	1.3	4
14	Hormones and Immune Responsiveness Chronic Lymphocytic ieukemia. Leukemia and Lymphoma, 1992, 8, 483-489.	1.3	9
15	CD13 Expression in B-Cell Chronic Lymphocytic Leukemia is Associated with the Pattern of Bone Marrow Infiltration. Leukemia and Lymphoma, 1992, 6, 209-218.	1.3	18
16	Expression of Ki-67 nuclear antigen in B and T cell lymphoproliferative disorders Journal of Clinical Pathology, 1992, 45, 660-663.	2.0	18
17	A Prospective Study of the Evolution of Chronic Lymphocytic Leukaemia. Leukemia and Lymphoma, 1992, 7, 87-97.	1.3	5
18	A Clinical Update on Chronic Lymphocytic Leukemia. I. Diagnosis and Prognosis. Mayo Clinic Proceedings, 1992, 67, 349-353.	3.0	17

#	Article	IF	CITATIONS
19	A Clinical Update on Chronic Lymphocytic Leukemia. II. Critical Analysis of Current Chemotherapeutic Modalities. Mayo Clinic Proceedings, 1992, 67, 457-461.	3.0	13
20	Surface immunoglobulin density in the differential diagnosis of B-cell chronic lymphocytic leukemia and leukemic immunocytoma. Leukemia Research, 1992, 16, 191-196.	0.8	4
21	Prognostic significance of the heterogenous expression of IgG Fc receptors in B-cell chronic lymphocytic leukemia. Annals of Hematology, 1992, 64, 140-145.	1.8	6
22	6 Chronic lymphocytic leukaemia: Prognostic factors and natural history. Best Practice and Research: Clinical Haematology, 1993, 6, 849-866.	1.1	34
23	7 Treatment of chronic lymphocytic leukaemia. Best Practice and Research: Clinical Haematology, 1993, 6, 867-878.	1.1	15
24	8 Intensive therapy of chronic lymphocytic leukaemia. Best Practice and Research: Clinical Haematology, 1993, 6, 879-885.	1.1	4
25	The chronic B ell leukaemias. Australian and New Zealand Journal of Medicine, 1993, 23, 42-50.	0.5	7
26	Splenectomy in Lymphoproliferative Disorders: A Report on 70 Cases and Review of the Literature. Leukemia and Lymphoma, 1993, 10, 245-264.	1.3	39
27	Proliferating Cell Nuclear Antigen (PCNA) Expression in Chronic Lymphocytic Leukemia (CLL). Leukemia and Lymphoma, 1993, 10, 265-271.	1.3	23
28	Marrow Histomorphology and Clinical Staging of Chronic Lymphocytic Leukemia-A Rare Disease in India: Experience with 26 Cases. Leukemia and Lymphoma, 1993, 10, 117-119.	1.3	1
29	FLOW-CYTOMETRY DETECTION OF MINIMAL DNA ANEUPLOIDY IN MATURE LYMPHOID LEUKEMIAS - COMPARISON WITH METAPHASE AND INTERPHASE CYTOGENETICS. International Journal of Oncology, 1994, 5, 211-214.	3.3	4
30	Morphological and Immunophenotypical Characterization of Japanese B-Cell Lymphocytic Leukemia. Leukemia and Lymphoma, 1994, 16, 113-119.	1.3	8
31	Fludarabine in Lymphoproliferative Disorders: The Royal Marsden Hospital Experience. Leukemia and Lymphoma, 1994, 14, 17-23.	1.3	17
32	The spectrum of chronic lymphoproliferative disorders in Chinese people. Cancer, 1994, 74, 174-181.	4.1	27
33	The management of chronic lymphocytic leukemia at a single centre over a 24-year period: prognostic factors for survival. Hematological Oncology, 1994, 12, 29-39.	1.7	15
34	Chemomodulation of drugs involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type. Cancer Chemotherapy and Pharmacology, 1994, 34, 307-316.	2.3	3
35	Incidence of Chronic Lymphocytic Leukemia in Olmsted County, Minnesota, 1935 Through 1989, With Emphasis on Changes in Initial Stage at Diagnosis. Mayo Clinic Proceedings, 1994, 69, 323-328.	3.0	73
36	Chronic Lymphocytic Leukemia. American Journal of the Medical Sciences, 1994, 308, 196-200.	1.1	5

		ion Report	
#	Article	IF	CITATIONS
37	The management of chronic lymphocytic leukemia – a case history. Annals of Oncology, 1995, 6, 71-76.	1.2	3
38	Chronic lymphocytic leukemia: Present status. Annals of Oncology, 1995, 6, 219-235.	1.2	51
39	Key issues in the treatment of chronic lymphocytic leukaemia (CLL). European Journal of Cancer, 1995, 31, 2146-2154.	2.8	15
40	Chronic Lymphocytic Leukemia. New England Journal of Medicine, 1995, 333, 1052-1057.	27.0	744
41	Karyotypic and molecular abnormalities in chronic lymphocytic leukaemia. Journal of Clinical Pathology, 1996, 49, M185-M191.	1.9	5
42	Interferon-alpha 2b (IFNα) for Early-Phase Chronic Lymphocytic Leukaemia with High Risk for Disease Progression: Results of a Randomized Multicentre Study. British Journal of Haematology, 1996, 94, 362-369.	2.5	17
43	The Impact of Molecular Cytogenetics on Chronic Lymphoid Leukaemia. Acta Haematologica, 1997, 98, 175-186.	1.4	16
44	The Relevance of Cytological Studies and Ki-67 Reactivity to the Clinical Course of Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 1997, 26, 337-342.	1.3	11
45	Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations. Aging Clinical and Experimental Research, 1997, 9, 383-390.	2.9	1
46	Myelodysplasia nd the leukemias. Disease-a-Month, 1997, 43, 507-597.	1.1	6
47	High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Cancer, 1997, 79, 2107-2114.	4.1	71
48	Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. Leukemia, 1998, 12, 1699-1707.	7.2	45
49	Trisomy 12 in chronic lymphocytic leukemia—geographical variation. Leukemia Research, 1998, 22, 313-317.	0.8	13
50	Detection of Trisomy 12 and Centromeric Alterations in CLL by Interphase- and Metaphase-FISH. Cancer Genetics and Cytogenetics, 1998, 100, 148-151.	1.0	6
51	Differences in rhodamine-123 efflux in B-type chronic lymphocytic leukemia suggest possible gender and stage variations in drug-resistance gene activity. Annals of Hematology, 1998, 76, 189-194.	1.8	19
52	Myelodysplasia and the leukemias. Current Problems in Cancer, 1998, 22, 384-464.	2.0	0
53	p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis. Blood, 1998, 91, 4342-4349.	1.4	176
54	Two Oral Trofosfamide Schedules in Elderly Patients with Refractory Non-Hodgkinâ€~s Lymphoma. Oncology Research and Treatment, 1999, 22, 134-138.	1.2	6

#	Article	IF	CITATIONS
55	Second Malignancies as a Consequence of Nucleoside Analog Therapy for Chronic Lymphoid Leukemias. Journal of Clinical Oncology, 1999, 17, 2454-2454.	1.6	195
56	lg V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia. Blood, 1999, 94, 1840-1847.	1.4	2,291
57	2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia, 1999, 13, 518-523.	7.2	38
58	Cyclin D1 overexpression allows identification of an aggressive subset of leukemic lymphoproliferative disorder. Leukemia, 1999, 13, 1343-1351.	7.2	40
59	Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study. Bone Marrow Transplantation, 1999, 24, 989-993.	2.4	21
60	Is there still a place for clinical staging in chronic lymphocytic leukaemia?. Leukemia Research, 1999, 23, 589-592.	0.8	2
61	The National Cancer Data Base Report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer, 1999, 86, 2684-2692.	4.1	103
62	The DiSC ASSAY. International Journal of Technology Assessment in Health Care, 1999, 15, 173-184.	0.5	26
63	Cladribine with or without prednisone in the treatment of previously treated and untreated B ell chronic lymphocytic leukaemia — updated results of the multicentre study of 378 patients. British Journal of Haematology, 2000, 108, 357-368.	2.5	77
64	Management of Chronic Lymphocytic Leukaemia. Drugs and Aging, 2000, 16, 9-27.	2.7	40
65	Infection and Immunity in Chronic Lymphocytic Leukemia. Mayo Clinic Proceedings, 2000, 75, 1039-1054.	3.0	124
66	Cladribine in the Treatment of Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 2001, 40, 551-564.	1.3	46
68	Chronic lymphocytic leukaemia. Clinical Medicine, 2001, 1, 350-353.	1.9	0
69	Monoclonal B lymphocytes with the characteristics of "indolent―chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood, 2002, 100, 635-639.	1.4	305
70	Chronic Lymphocytic Leukaemia—the Haematologic Basis for Diagnosis and Treatment. Hematology, 2002, 7, 33-42.	1.5	2
71	Refining prognostic factors in chronic lymphocytic leukemia. Reviews in Clinical and Experimental Hematology, 2002, 6, 335-349.	0.1	9
72	Bâ€chronic lymphocytic leukemia: practical aspects. Hematological Oncology, 2002, 20, 103-146.	1.7	41
73	The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer, 2002, 94, 1721-1730.	4.1	48

	CITATION	N REPORT	
#	Article	IF	CITATIONS
74	Symptoms and prognosis in advanced cancer. Supportive Care in Cancer, 2002, 10, 385-388.	2.2	66
75	Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. British Journal of Haematology, 2003, 120, 759-764.	2.5	115
76	Biology and Treatment of Chronic Lymphocytic Leukemia. Hematology American Society of Hematology Education Program, 2003, 2003, 153-175.	2.5	96
77	CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. The Hematology Journal, 2004, 5, 145-151.	1.4	47
78	Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. British Journal of Haematology, 2004, 125, 294-317.	2.5	134
79	Advancing Therapy For Chronic Lymphocytic Leukemia–the Role Of Rituximab. Seminars in Oncology, 2004, 31, 22-26.	2.2	11
80	In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochemical Pharmacology, 2004, 68, 2409-2416.	4.4	89
81	The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia. Cancer, 2004, 100, 2167-2175.	4.1	13
82	Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer, 2004, 100, 2583-2591.	4.1	40
83	Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood, 2004, 103, 1202-1210.	1.4	214
84	Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia. Mayo Clinic Proceedings, 2004, 79, 388-398.	3.0	35
85	Clinical staging and prognostic markers in chronic lymphocytic leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 795-805.	2.2	23
86	Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood, 2005, 106, 3175-3182.	1.4	209
87	Stem cell transplantation for chronic lymphocytic leukaemia. British Journal of Haematology, 2005, 128, 145-152.	2.5	32
88	Ethnicity variables in the incidence rates of leukemias in New Zealand populations: Implications for stem-cell transplantation. American Journal of Hematology, 2005, 79, 114-118.	4.1	5
89	A Population-based Assessment of the Prognostic Value of the CD19 Positive Lymphocyte Count in B-cell Chronic Lymphocytic Leukemia using Cox and Markov Models. European Journal of Epidemiology, 2005, 20, 993-1001.	5.7	2
90	Treatment of Chronic Lymphocytic Leukemia: Achieving Minimal Residual Disease–Negative Status As a Goal. Journal of Clinical Oncology, 2005, 23, 2884-2885.	1.6	34
91	Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival. Journal of Clinical Oncology, 2005, 23, 2971-2979.	1.6	380

#	Article	IF	Citations
92	Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood, 2005, 105, 397-404.	1.4	107
93	Changes in leukemic cell nuclei revealed by differential scanning calorimetry. Leukemia and Lymphoma, 2005, 46, 121-128.	1.3	8
94	Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leukemia and Lymphoma, 2006, 47, 1477-1480.	1.3	81
95	Evaluation of clinical staging in chronic lymphocytic leukemia- population-based study. Leukemia and Lymphoma, 2006, 47, 2505-2516.	1.3	17
96	CLL: chromosomal abnormalities (FISH) and their relation with clinical stage, CD38 and ZAP-70. Revista Brasileira De Hematologia E Hemoterapia, 2006, 28, 5.	0.7	1
97	Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood, 2006, 108, 473-479.	1.4	119
99	Narrative Review: Initial Management of Newly Diagnosed, Early-Stage Chronic Lymphocytic Leukemia. Annals of Internal Medicine, 2006, 145, 435.	3.9	55
101	High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia. British Journal of Haematology, 2006, 133, 173-175.	2.5	25
102	Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood, 2007, 109, 4679-4685.	1.4	303
103	The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma—a population-based study. Leukemia and Lymphoma, 2007, 48, 736-745.	1.3	37
104	Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood, 2007, 110, 735-742.	1.4	155
105	The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 2008, 77, 460-465.	2.5	35
106	Chronic lymphocytic leukaemia: prognostic value of lymphocyte morphological subtypes. A multivariate survival analysis in 146 patients. British Journal of Haematology, 2008, 77, 478-485.	2.5	60
107	Indolent Lymphomas Other than Follicular and Marginal Zone Lymphomas. Hematology/Oncology Clinics of North America, 2008, 22, 903-940.	2.2	5
108	Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies. Nature Clinical Practice Oncology, 2008, 5, 316-323.	4.3	8
109	Mature B-Cell Neoplasms. , 2008, , 297-372.		9
110	Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2009, 27, 3808-3814.	1.6	161
111	Bâ€chronic lymphocytic leukaemia in Latvia: Epidemiological aspects. European Journal of Haematology, 1993, 51, 214-217.	2.2	2

#	Article	IF	CITATIONS
112	Comparison of younger versus older Bâ€cell chronic lymphocytic leukemia patients for clinical presentation and prognosis. A retrospective study of 53 cases. European Journal of Haematology, 1994, 52, 216-221.	2.2	28
113	Chronic lymphocytic leukemia: A retrospective study of 122 cases. European Journal of Haematology, 1994, 52, 108-114.	2.2	6
114	Treatment of chronic lymphocytic leukemia in early and stable phase of the disease: Longâ€ŧerm results of a randomized trial. European Journal of Haematology, 1995, 55, 158-163.	2.2	21
115	High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: A population-based Canadian cohort. Leukemia Research, 2009, 33, 1463-1468.	0.8	47
116	Prognostic markers in chronic lymphocytic leukemia: A comprehensive review. Blood Reviews, 2009, 23, 25-47.	5.7	100
117	Facteurs pronostiques utiles dans l'évaluation personnalisée d'un patient avec une leucémie lymphoÃ⁻de chronique (LLC). Immuno-Analyse Et Biologie Specialisee, 2009, 24, 1-8.	0.0	0
118	Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital ClÃnic of Barcelona experience. Blood, 2009, 114, 2044-2050.	1.4	132
119	B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood, 2009, 113, 4188-4196.	1.4	104
120	Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer, 2010, 116, 4777-4787.	4.1	107
121	Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia, 2010, 24, 788-797.	7.2	132
122	Prognostic Markers and Stratification of Chronic Lymphocytic Leukemia. Hematology American Society of Hematology Education Program, 2010, 2010, 77-81.	2.5	35
123	Effect of ligand-activated estrogen receptor β on lymphoma growth in vitro and in vivo. Leukemia, 2011, 25, 1103-1110.	7.2	62
124	Prognostic factors in chronic lymphocytic leukemia—what do we need to know?. Nature Reviews Clinical Oncology, 2011, 8, 38-47.	27.6	150
125	Dequalinium induces apoptosis in peripheral blood mononuclear cells isolated from human chronic lymphocytic leukemia. Investigational New Drugs, 2011, 29, 1156-1163.	2.6	20
126	Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80Âyears or more. An ICLLSG study. Annals of Hematology, 2011, 90, 1123-1129.	1.8	12
127	The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience. American Journal of Hematology, 2011, 86, 1007-1012.	4.1	47
128	Monoclonal B-lymphocytosis: demographics, nature and subclassification in 414 community patients. Leukemia and Lymphoma, 2011, 52, 2293-2298.	1.3	15
129	Nitric Oxide–Donating Acetylsalicylic Acid Induces Apoptosis in Chronic Lymphocytic Leukemia Cells and Shows Strong Antitumor Efficacy <i>In vivo</i> . Clinical Cancer Research, 2011, 17, 286-293.	7.0	18

#	Article	IF	CITATIONS
130	ZGDHu-1 promotes apoptosis of chronic lymphocytic leukemia cells. International Journal of Oncology, 2012, 41, 533-540.	3.3	15
131	Predicting survival in chronic lymphocytic leukemia. Expert Review of Anticancer Therapy, 2012, 12, 393-403.	2.4	18
132	Optimal management of older patients with chronic lymphocytic leukemia: Some facts and principles guiding therapeutic choices. Blood Reviews, 2012, 26, 15-23.	5.7	14
133	Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer, 2013, 119, 363-370.	4.1	147
134	Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. Supportive Care in Cancer, 2013, 21, 2853-2860.	2.2	26
135	A History of the Chronic Leukemias. , 2013, , 3-10.		0
136	Treatment of Chronic Lymphocytic Leukemia and Related Disorders. , 2013, , 103-119.		0
137	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study. Leukemia and Lymphoma, 2013, 54, 53-57.	1.3	42
138	Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood, 2013, 121, 3818-3824.	1.4	153
139	Improving but Inferior Survival in Patients with Chronic Lymphocytic Leukemia in Taiwan: A Population-Based Study, 1990–2004. PLoS ONE, 2013, 8, e62930.	2.5	17
140	Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study. Leukemia and Lymphoma, 2014, 55, 1838-1843.	1.3	16
141	The clinical significance of patients' sex in chronic lymphocytic leukemia. Haematologica, 2014, 99, 1088-1094.	3.5	55
142	Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. Blood, 2015, 125, 492-498.	1.4	47
143	Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. Cancer, 2015, 121, 2883-2891.	4.1	77
144	Systematic review/Meta-analysis The role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: a meta-analysis. Archives of Medical Science, 2015, 4, 708-714.	0.9	22
145	A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry. Leukemia and Lymphoma, 2015, 56, 2556-2562.	1.3	19
146	Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients. Blood Cancer Journal, 2016, 6, e499-e499.	6.2	47
147	Estrogen receptor \hat{I}^21 in diffuse large B-cell lymphoma growth and as a prognostic biomarker. Leukemia and Lymphoma, 2017, 58, 418-427.	1.3	13

#	Article	IF	CITATIONS
148	Estrogen promotes megakaryocyte polyploidization via estrogen receptor beta-mediated transcription of GATA1. Leukemia, 2017, 31, 945-956.	7.2	28
149	The emerging role of estrogen in B cell malignancies. Leukemia and Lymphoma, 2017, 58, 528-539.	1.3	25
150	Treatment of Chronic Lymphocytic Leukemia and Related Disorders. , 2018, , 117-134.		0
151	Complex karyotype as a predictor of high-risk chronic lymphocytic leukemia: A single center experience over 12 years. Leukemia Research, 2019, 85, 106218.	0.8	9
152	Clinical presentation and hematological profile among young and old chronic lymphocytic leukemia patients in Sudan. BMC Research Notes, 2019, 12, 202.	1.4	11
153	Expression and Effects of Ligand-activated Estrogen Receptors in Chronic Lymphocytic Leukemia. Anticancer Research, 2019, 39, 167-172.	1.1	6
154	Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. The Cochrane Library, 2020, 2020, CD012022.	2.8	23
155	From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct. Cancers, 2021, 13, 1782.	3.7	10
156	Clinical and Laboratory Parameters That Define Clinically Relevant B-CLL Subgroups. , 2005, 294, 109-133.		11
157	Expression of myelomonocytic antigens is associated with unfavourable clinicoprognostic factors in B-cell chronic lymphocytic leukaemia. , 1991, 2 Suppl 2, 107-113.		14
158	Chemotherapy of the Leukaemias. , 1990, , 5-77.		2
159	Phase II Study of 2-Chlorodeoxyadenosine in Combination With Chlorambucil in Previously Untreated B-Cell Chronic Lymphocytic Leukemia. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 509.	1.3	14
160	Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments]. Blood, 1996, 88, 3-40.	1.4	420
161	p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis. Blood, 1998, 91, 4342-4349.	1.4	112
162	lg V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia. Blood, 1999, 94, 1840-1847.	1.4	46
163	Standardized Extract of the Persian Gulf Sponge, Axinella Sinoxea Selectively Induces Apoptosis through Mitochondria in Human Chronic Lymphocytic Leukemia Cells. Journal of Analytical Oncology, 2015, 4, 132-40.	0.1	7
164	Prognostic Indicators of Chronic Lymphocytic Leukemia. , 2004, , 201-215.		1
165	Chronische lymphatische Leukänie. , 2004, , 1975-2000.		0

#	Article	IF	CITATIONS
166	Marcadores de prognóstico na leucemia linfocÃtica crônica. Revista Brasileira De Hematologia E Hemoterapia, 2005, 27, .	0.7	1
167	Indicações para inÃcio de tratamento na leucemia linfóide crônica. Revista Brasileira De Hematologia E Hemoterapia, 2005, 27, .	0.7	0
168	Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. , 2006, , 406-414.		0
170	Prognostic Significance of Bone-marrow Pattern and Immunophenotypic Score in B-chronic Lymphocytic Leukemia at Diagnosis. Medicinski Arhiv = Medical Archives = Archives De Médecine, 2011, 65, 132.	0.9	3
171	Prognostic Factors in Chronic Lymphoid Leukemia and Identification of New Clinically Relevant Molecular Markers. , 0, , .		1
172	Expression of Low Molecular Weight Proteins in Patients with Leukaemia. West Indian Medical Journal, 2012, 61, 235-239.	0.4	3
174	Evaluation of Reproducibility of Prognostic Index and Nomogram in Prognosis, and Therapeutically Approach of Patients with Chronic Lymphocytic Leukaemia-Single Centre Experience. Science Journal of Clinical Medicine, 2014, 3, 124.	0.1	0
175	Hänatologische Neoplasien: Klinisch latent — aber behandlungsbedürftig?. Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin, 1990, , 138-147.	0.0	0
176	Presenting features and prognosis of chronic lymphocytic leukemia in younger adults [see comments]. Blood, 1991, 78, 1545-1551.	1.4	11
178	Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: analysis by stage, immunophenotype, and morphology. Blood, 1993, 82, 571-575.	1.4	44
179	The management of chronic lymphocytic leukemia $\hat{a} {\in} "$ a case history. , 1997, , 57-62.		0
180	Blood Disorders in the Elderly. , 2016, , 95-116.		0
181	Lymphoproliferative Disorders. , 2017, , 1-7.		0
182	Lymphoproliferative Disorders. , 2018, , 259-265.		0
183	Chronic lymphocytic leukaemia: a-twenty-years experience and problems in Ile-Ife, South-Western Nigeria. African Health Sciences, 2010, 10, 187-92.	0.7	14
184	Impact of clinical staging and demographic data (age and sex) on response to treatment and survival of chronic lymphocytic leukemia patients in Kurdistan Region of Iraq. Iraqi Journal of Hematology, 2021, 10, 102.	0.1	2
185	Prognostic value of CD20 antigen mediated immune checkpoint inhibition in patients with acute or chronic lymphocytic leukemia. Medicine (United States), 2022, 101, e28868.	1.0	0
187	Chronic Lymphocytic Leukemia: Diagnosis and Management. , 0, , 23-54.		0

#	Article	IF	CITATIONS
188	Early clinical trials in chronic lymphocytic leukaemia in the UK. British Journal of Haematology, 2020, 191, 535-541.	2.5	0
189	Is it possible to apply individual treatments in patients with chronic lymphocytic leukemia?. , 2013, 47, 5-10.		0
190	Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma. Cancers, 2022, 14, 2932.	3.7	5
191	Estrogens revert neutrophil hyperplasia by inhibiting Hif1α-cMyb pathway in zebrafish myelodysplastic syndromes models. Cell Death Discovery, 2022, 8, .	4.7	1
192	Role of estrogen receptor signaling pathway-related genes in diffuse large B-cell lymphoma and identification of key targets via integrated bioinformatics analysis and experimental validation. Frontiers in Oncology, 0, 12, .	2.8	1